Skip to main content

Advertisement

Table 1 Comparison of demographic and clinical characteristics between patients with / without gastric cancer recurrence

From: CD44/CD24 Expression in recurrent gastric cancer: a retrospective analysis

Characteristics Study Group Control Group  P -value
  (n = 20) (n = 20)  
  Recurrence Non-recurrence  
Gender, n(%)
Male 12 (60.0) 7 (35.0) 0.113†
Female 8 (40.0) 13 (65.0)  
Age (years)
mean ± SD 71.2 ± 10.6 65.7 ± 11.7 0.128‡
Age group, n(%)
≤65 6 (30.0) 10 (50.0) 0.197†
>65 14 (70.0) 10 (50.0)  
Histology, n(%)
Moderately differentiated (intestinal type) 9 (45.0) 6 (30.0) 0.327†
Poorly differentiated (diffuse type) 11 (55.0) 14 (70.0)  
Tumor location, n(%)
Upper third of stomach 5 (25.0) 10 (50.0) 0.191¶
Middle third of stomach 1 (5.0) 0 (0.0)  
Lower third of stomach 14 (70.0) 10 (50.0)  
TNM Stage, n(%)
I-IIa 4 (20.0) 15 (75.0) 0.001*†
III-IV 16 (80.0) 5 (25.0)  
Lymph node metastasis, n(%)
No 2 (10.0) 11 (55.0) 0.002*†
Yes 18 (90.0) 9 (45.0)  
Number of lymph node metastasis, n(%)
0 2 (10.0) 11 (55.0) 0.007*†
1-4 s 9 (45.0) 6 (30.0)  
≥5 9 (45.0) 3 (15.0)  
CD44 expression, n(%)
CD44- 10 (50.0) 10 (50.0) 1.000†
CD44+ 10 (50.0) 10 (50.0)  
CD24 expression, n(%)
CD24- 10 (50.0) 13 (65.0) 0.337†
CD24+ 10 (50.0) 7 (35.0)  
CD44 / CD24 expression, n(%)
CD44-/CD24- 5 (25.0) 8 (40.0) 0.622¶
CD44-/CD24+ 5 (25.0) 2 (10.0)  
CD44+/CD24- 5 (25.0) 5 (25.0)  
CD44+/CD24+ 5 (25.0) 5 (25.0)  
  1. a Two control patients with TNM Stage 0 were grouped into Stage I-II.
  2. *P<0.05.
  3. † Chi-square test; ‡ independent t-test; ¶Fisher’s exact test.